Vanguard Group
PCVX icon

Vanguard Group’s Vaxcyte PCVX Stock Holding History

Vanguard Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$563M Sell
12,193,986
-126,467
-1% -$5.66M 0.01% 988
2025
Q3 		$444M Buy
12,320,453
+323,368
+3% +$10.7M 0.01% 1126
2025
Q2 		$390M Sell
11,997,085
-46,720
-0.4% -$1.53M 0.01% 1166
2025
Q1 		$455M Buy
12,043,805
+82,118
+0.7% +$6.57M 0.01% 1044
2024
Q4 		$979M Buy
11,961,687
+521,204
+5% +$51.8M 0.02% 667
2024
Q3 		$1.31B Buy
11,440,483
+1,643,488
+17% +$148M 0.02% 583
2024
Q2 		$740M Buy
9,796,995
+59,741
+0.6% +$4.07M 0.01% 772
2024
Q1 		$665M Buy
9,737,254
+1,284,883
+15% +$89M 0.01% 852
2023
Q4 		$531M Buy
8,452,371
+168,125
+2% +$8.73M 0.01% 934
2023
Q3 		$422M Buy
8,284,246
+47,872
+0.6% +$2.36M 0.01% 987
2023
Q2 		$411M Buy
8,236,374
+1,704,058
+26% +$80.8M 0.01% 1041
2023
Q1 		$245M Sell
6,532,316
-81,350
-1% -$3.45M 0.01% 1346
2022
Q4 		$317M Buy
6,613,666
+2,161,521
+49% +$84.8M 0.01% 1137
2022
Q3 		$107M Buy
4,452,145
+496,227
+13% +$12.6M ﹤0.01% 1747
2022
Q2 		$86.1M Buy
3,955,918
+326,554
+9% +$7.56M ﹤0.01% 1912
2022
Q1 		$87.6M Buy
3,629,364
+495,078
+16% +$10.8M ﹤0.01% 2016
2021
Q4 		$74.6M Buy
3,134,286
+90,404
+3% +$2.1M ﹤0.01% 2131
2021
Q3 		$77.2M Buy
3,043,882
+195,238
+7% +$4.73M ﹤0.01% 2130
2021
Q2 		$64.1M Buy
2,848,644
+77,330
+3% +$1.58M ﹤0.01% 2238
2021
Q1 		$54.7M Buy
2,771,314
+1,321,937
+91% +$33.3M ﹤0.01% 2264
2020
Q4 		$38.5M Buy
1,449,377
+96,557
+7% +$3.59M ﹤0.01% 2334
2020
Q3 		$66.8M Buy
1,352,820
+1,322,820
+4,409% +$52.7M ﹤0.01% 1871
2020
Q2 		$948K Buy
+30,000
New +$965K ﹤0.01% 3626

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Group's PCVX Position: Q4 2025 in Review

Vanguard Group reduced its Vaxcyte (PCVX) stake by 1% in Q4 2025, selling an estimated $5.66M and leaving 12,193,986 shares worth $563M. The position accounts for 0.01% of the portfolio, ranked #988.

Vanguard Group first reported a position in PCVX in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.31B in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Vanguard Group held 12,193,986 shares of Vaxcyte worth $563M as of Q4 2025.
  • Vanguard Group sold 126,467 Vaxcyte shares in Q4 2025, an estimated $5.66M.
  • Vaxcyte made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #988 holding.
  • Vanguard Group first reported a position in Vaxcyte in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Vaxcyte position peaked at $1.31B in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.